INEC Killarney Convention Centre Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Microbiome: Therapeutic Implications (T1)
Organizer(s) Justin L. Sonnenburg, Fergus Shanahan and Suzanne Devkota
October 6—10, 2019
INEC Killarney Convention Centre • Killarney, Co. Kerry Ireland
Discounted Abstract Deadline: Jun 6, 2019
Abstract Deadline: Jul 9, 2019
Scholarship Deadline: Jun 6, 2019
Discounted Registration Deadline: Aug 7, 2019
Supported by the Directors' Fund
Summary of Meeting:
The microbial communities that inhabit the human body are connected to diverse aspects of our health. The plasticity and individuality of these communities promise great potential in the emerging vision of precision health, but formidable gaps to realizing this potential must be addressed. Critical challenges include the intrinsic complexity of dynamic microbial ecosystems, understanding how these microbes mechanistically connect to human biology, and identifying key therapeutic opportunities. This conference will bring together leaders across a range of disciplines from both academia and industry in microbiome sciences to present recent progress and innovative directions at addressing these gaps. This conference will provide a detailed view of the current status, future vision, and challenges of key modalities for predicting, diagnosing, and treating disease via the microbiome. In addition, there will be topics which augment the traditional biomedical paradigm of developing diagnostics and treatments with orthogonal approaches, such as pre-therapeutic prevention and health optimization strategies. Invited speakers will present key technologies and approaches for propelling the coming phases of basic and translational microbiome research. Finally, participants will receive key information about the current regulatory environment for microbial therapeutics. With the rapid expansion of translational microbiome efforts, this conference will enable synergies through the aggregation of knowledge and experiences from diverse body sites, disease states, and approaches. We combine facets of basic sciences including evolution, ecology, and technology development so an interdisciplinary collection of scientists can elucidate key steps for establishing a strong pipeline from fundamental understanding to therapeutic realization.
View Scholarships/Awards
The microbial communities that inhabit the human body are connected to diverse aspects of our health. The plasticity and individuality of these communities promise great potential in the emerging vision of precision health, but formidable gaps to realizing this potential must be addressed. Critical challenges include the intrinsic complexity of dynamic microbial ecosystems, understanding how these microbes mechanistically connect to human biology, and identifying key therapeutic opportunities. This conference will bring together leaders across a range of disciplines from both academia and industry in microbiome sciences to present recent progress and innovative directions at addressing these gaps. This conference will provide a detailed view of the current status, future vision, and challenges of key modalities for predicting, diagnosing, and treating disease via the microbiome. In addition, there will be topics which augment the traditional biomedical paradigm of developing diagnostics and treatments with orthogonal approaches, such as pre-therapeutic prevention and health optimization strategies. Invited speakers will present key technologies and approaches for propelling the coming phases of basic and translational microbiome research. Finally, participants will receive key information about the current regulatory environment for microbial therapeutics. With the rapid expansion of translational microbiome efforts, this conference will enable synergies through the aggregation of knowledge and experiences from diverse body sites, disease states, and approaches. We combine facets of basic sciences including evolution, ecology, and technology development so an interdisciplinary collection of scientists can elucidate key steps for establishing a strong pipeline from fundamental understanding to therapeutic realization.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, October 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, October 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, October 11 in order to fully experience the meeting.
SUNDAY, OCTOBER 6
MONDAY, OCTOBER 7
TUESDAY, OCTOBER 8
WEDNESDAY, OCTOBER 9
THURSDAY, OCTOBER 10
FRIDAY, OCTOBER 11
Conference Program Print | View meeting in 24 hr (international) time
The meeting will begin on Sunday, October 6 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, October 10 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, October 11 in order to fully experience the meeting.
SUNDAY, OCTOBER 6
4:00—8:00 PM
Arrival and Registration
Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
Foyer
8:30—9:30 AM
Welcome and Keynote Address
Main Auditorium
*
Fergus Shanahan,
National University of Ireland, Ireland
David A. Relman,
Stanford University, USA
Humans, History and the Study of Microbiomes: Where Have We Been, Where do We Need to Go?
Humans, History and the Study of Microbiomes: Where Have We Been, Where do We Need to Go?
9:30 AM—12:00 PM
Live Microbial Therapeutics
Main Auditorium
*
Elena F. Verdu,
McMaster University, Canada
Bernat Olle,
Vedanta Biosciences, USA
Medicines Based on Defined Bacterial Consortia
Medicines Based on Defined Bacterial Consortia
Coffee Break
Ian A. Myles,
NIAID, National Institutes of Health, USA
Short Talk: First-in-Human Topical Microbiome Transplantation with Roseomonas Mucosa for Atopic Dermatitis: Clinical Outcomes and Mechanistic Insights
Short Talk: First-in-Human Topical Microbiome Transplantation with Roseomonas Mucosa for Atopic Dermatitis: Clinical Outcomes and Mechanistic Insights
Alice Cheng,
Stanford University, USA
Short Talk: Design and Therapeutic Application of a Highly Complex Synthetic Microbial Community
Short Talk: Design and Therapeutic Application of a Highly Complex Synthetic Microbial Community
Jessica Ravikoff Allegretti,
Brigham and Women's Hospital, USA
FMT for C. difficile and Beyond
FMT for C. difficile and Beyond
Paul E. Carlson,
US Food and Drug Administration, USA
Regulatory Considerations for Microbiome Related Products
Regulatory Considerations for Microbiome Related Products
12:00—5:00 PM
On Own for Lunch
12:00—1:00 PM
Poster Setup
Foyer
1:00—10:00 PM
Poster Viewing
Foyer
2:30—4:30 PM
Workshop 1: Microbiome Science: Human-Centered Studies
Main Auditorium
*
Tzu-Wen L. Cross,
Purdue University, USA
Michael Woodworth,
Emory University School of Medicine, USA
Clearance of Antibiotic-Resistant Enterobacteriaceae after Stool Enema Shown by Genome Sequencing of Stool-Derived and Clinical Isolates
Clearance of Antibiotic-Resistant Enterobacteriaceae after Stool Enema Shown by Genome Sequencing of Stool-Derived and Clinical Isolates
Jessica McCann,
Duke University, USA
Deciphering the Contribution of the Microbiome to Branched Chain Amino Acid (BCAA) Metabolism and Obesity in Adolescents and Mice
Deciphering the Contribution of the Microbiome to Branched Chain Amino Acid (BCAA) Metabolism and Obesity in Adolescents and Mice
Anubhav Das,
4D Pharma Cork Ltd, Ireland
Impact of a Live Biotherapeutic on the Structure of the Gut Microbiota – Results from the Blautix Phase I Study in Irritable Bowel Syndrome
Impact of a Live Biotherapeutic on the Structure of the Gut Microbiota – Results from the Blautix Phase I Study in Irritable Bowel Syndrome
Julia Copeland,
University of Toronto, Canada
The Impact of Immigration on the Gut Metagenome of South Asian Canadians
The Impact of Immigration on the Gut Metagenome of South Asian Canadians
Carles Lerin,
Hospital Sant Joan de Deu, Spain
Effects of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) on Children with Prader-Willi Syndrome: A Randomized Crossover Trial
Effects of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) on Children with Prader-Willi Syndrome: A Randomized Crossover Trial
Philippa Margaret Wells,
King's College London, UK
Genetic Risk of Rheumatoid Arthritis is Associated with the Oral and Gut Microbiota
Genetic Risk of Rheumatoid Arthritis is Associated with the Oral and Gut Microbiota
Madelief Wijdeveld,
Amsterdam University Medical Center, Netherlands
Relation Between Intestinal Acetate Production and Plasma Glucose Levels in Healthy Subjects
Relation Between Intestinal Acetate Production and Plasma Glucose Levels in Healthy Subjects
Christopher B. Ford,
Seres Therapeutics, USA
Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin is Associated with Reduced Rates of Recurrence after Primary Clostridium difficile Infection (CDI)
Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin is Associated with Reduced Rates of Recurrence after Primary Clostridium difficile Infection (CDI)
4:30—5:00 PM
Coffee Available
Foyer
5:00—7:00 PM
Using the Microbiome to Alter Immune Status: Beyond Colonic Bacteria
Main Auditorium
*
Justin L. Sonnenburg,
Stanford University, USA
David M. Underhill,
Cedars-Sinai Medical Center, USA
A Role for the Fungal Microbiota in Crohn’s Disease?
A Role for the Fungal Microbiota in Crohn’s Disease?
Susan V. Lynch,
University of California, San Francisco, USA
Infant Probiotics to Combat Allergies and Asthma
Infant Probiotics to Combat Allergies and Asthma
Elena F. Verdu,
McMaster University, Canada
Small Intestinal Microbiome and Gluten Metabolism: A Missing Ingredient in Celiac Disease?
Small Intestinal Microbiome and Gluten Metabolism: A Missing Ingredient in Celiac Disease?
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Foyer
7:30—10:00 PM
Poster Session 1
Foyer
8:30—11:45 AM
Diet as a Lever for Altering the Microbiome
Main Auditorium
*
Suzanne Devkota,
Cedars-Sinai Medical Center, USA
Christopher J. Damman,
Bill & Melinda Gates Foundation, USA
Food, Microbes, and the Gut for Good Growth in Global Health
Food, Microbes, and the Gut for Good Growth in Global Health
Arjun Raman,
Washington University in St. Louis, USA
Short Talk: A Sparse Co-Varying Unit that Describes Healthy and Impaired Community Development
Short Talk: A Sparse Co-Varying Unit that Describes Healthy and Impaired Community Development
Paul W. O'Toole,
University College Cork, Ireland
The Impact of Diet on Microbiome in Aging
The Impact of Diet on Microbiome in Aging
Coffee Break
Brianna Petrone,
Duke University, USA
Short Talk: DNA Metabarcoding, a Molecular Diet Survey for Studies of Human Gut Microbiota
Short Talk: DNA Metabarcoding, a Molecular Diet Survey for Studies of Human Gut Microbiota
Liping Zhao,
Shanghai Jiao Tong University, China and Rutgers University, USA
Diets, Microbes and Diabetes
Diets, Microbes and Diabetes
Wenjie Ma,
Massachusetts General Hospital, USA
Short Talk: Dietary Fiber Intake, the Gut Microbiome, and Chronic Systemic Inflammation
Short Talk: Dietary Fiber Intake, the Gut Microbiome, and Chronic Systemic Inflammation
Ivan Vujkovic-Cvijin,
NIAID, National Institutes of Health, USA
Short Talk: Mining Immune Memory to Identify Pro-Inflammatory Gut Microbiota Members in Mice and Humans
Short Talk: Mining Immune Memory to Identify Pro-Inflammatory Gut Microbiota Members in Mice and Humans
Mark Sampson,
Azitra Inc., USA
Short Talk: Engineering the Skin Microbiome to Treat Skin Disease: A Phase I First-in-Human Safety Study with Topical Application of Engineered S. Epidermidis
Short Talk: Engineering the Skin Microbiome to Treat Skin Disease: A Phase I First-in-Human Safety Study with Topical Application of Engineered S. Epidermidis
11:45 AM—5:00 PM
On Own for Lunch
11:45 AM—1:00 PM
Poster Setup
Foyer
1:00—10:00 PM
Poster Viewing
Foyer
4:30—5:00 PM
Coffee Available
Foyer
5:00—7:00 PM
Controlling Microbial Metabolism
Main Auditorium
*
David A. Relman,
Stanford University, USA
Eric C. Martens,
University of Michigan Medical School, USA
Diet-Induced, Microbial Mucus Erosion as a Catalyst for Intestinal Diseases
Diet-Induced, Microbial Mucus Erosion as a Catalyst for Intestinal Diseases
Patricia Wolf,
University of Illinois at Urbana-Champaign, USA
Short Talk: Network Modeling of Bile Acid Metabolomics and Cecal Bacterial Metatranscriptomic Responses to Berberine in a Gnotobiotic Mouse Model Constituted with the B4PC2 Human Microbial Consortium
Short Talk: Network Modeling of Bile Acid Metabolomics and Cecal Bacterial Metatranscriptomic Responses to Berberine in a Gnotobiotic Mouse Model Constituted with the B4PC2 Human Microbial Consortium
Gary D. Wu,
University of Pennsylvania, USA
Engineering the Environment of the Gut to Modify the Gut Microbiota and its Metabolome
Engineering the Environment of the Gut to Modify the Gut Microbiota and its Metabolome
Will Van Treuren,
Stanford University, USA
Short Talk: Strain-Resolved Metabolomics of >150 Human Gut-Resident Bacterial Species Reveals Large-Scale Ecological Patterns, Novel Metabolic Strategies, and Widespread Production of Physiologically Relevant Molecules
Short Talk: Strain-Resolved Metabolomics of >150 Human Gut-Resident Bacterial Species Reveals Large-Scale Ecological Patterns, Novel Metabolic Strategies, and Widespread Production of Physiologically Relevant Molecules
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Foyer
7:30—10:00 PM
Poster Session 2
Foyer
8:00—8:30 AM
Poster Setup
Foyer
8:30 AM—5:00 PM
Poster Viewing
Foyer
8:30—11:45 AM
Looking to the Past, Predicting the Future
Main Auditorium
*
Kelly Swanson,
University of Illinois at Urbana-Champaign, USA
Justin L. Sonnenburg,
Stanford University, USA
Ancestral Microbes and Precision Human Interventions
Ancestral Microbes and Precision Human Interventions
Marsha C. Wibowo,
Harvard Medical School, USA
Short Talk: Reconstruction of Ancient Microbial Genomes from the Human Gut
Short Talk: Reconstruction of Ancient Microbial Genomes from the Human Gut
Nicolai Karcher,
University of Trento, Italy
Short Talk: Analysis of 1,321 Eubacterium Rectale Genomes from Metagenomes Unravels Complex Phylogeographic Population Structure and Subspecies Functional Adaptations
Short Talk: Analysis of 1,321 Eubacterium Rectale Genomes from Metagenomes Unravels Complex Phylogeographic Population Structure and Subspecies Functional Adaptations
Coffee Break
Susan Bullman,
Fred Hutchinson Cancer Research Center, USA
The Tumor Microbiota: A Role in Cancer Progression and Treatment
The Tumor Microbiota: A Role in Cancer Progression and Treatment
David Zeevi,
Rockefeller University, USA
Structural Variation in the Gut Microbiome Associates with Host Health
Structural Variation in the Gut Microbiome Associates with Host Health
Matthew R. Olm,
University of California, Berkeley, USA
Short Talk: Metagenomic Identification of Fecal Microbial Signatures Preceding Acute Intestinal Inflammation in Premature Infants
Short Talk: Metagenomic Identification of Fecal Microbial Signatures Preceding Acute Intestinal Inflammation in Premature Infants
Fergus Shanahan,
National University of Ireland, Ireland
Translating Microbiome Science – Lessons from the Past and Future Directions
Translating Microbiome Science – Lessons from the Past and Future Directions
11:45 AM—12:30 PM
Lunch
Foyer
12:00—2:30 PM
Poster Session 3
Foyer
2:30—4:30 PM
Workshop 2: Considerations for Conducting Human Trials and Testing Investigational New Drugs
Main Auditorium
*
Suzanne Devkota,
Cedars-Sinai Medical Center, USA
Paul E. Carlson,
US Food and Drug Administration, USA
Susan V. Lynch,
University of California, San Francisco, USA
Bernat Olle,
Vedanta Biosciences, USA
Jessica Ravikoff Allegretti,
Brigham and Women's Hospital, USA
4:30—5:00 PM
Coffee Available
Foyer
5:00—7:00 PM
Therapeutics - A Whole Body Approach
Main Auditorium
*
Premysl Bercik,
McMaster University, Canada
Purna C. Kashyap,
Mayo Clinic, USA
An Integrated Top Down and Bottom Up Strategy for Delineating the Role of Gut Microbiome in Functional Bowel Disorders
An Integrated Top Down and Bottom Up Strategy for Delineating the Role of Gut Microbiome in Functional Bowel Disorders
Hagit Shapiro,
Weizmann Institute of Science, Israel
Short Talk: Potential Roles of the Gut Microbiome in Modulation of Murine ALS
Short Talk: Potential Roles of the Gut Microbiome in Modulation of Murine ALS
John Cryan,
University College Cork, Ireland
Microbes and the Mind: Moving Toward Mechanisms
Microbes and the Mind: Moving Toward Mechanisms
Hannah Yan,
Baylor College of Medicine, USA
Short Talk: The Bacterial Microbiome Regulates Steady-State Hematopoiesis via Immune Signaling Pathways
Short Talk: The Bacterial Microbiome Regulates Steady-State Hematopoiesis via Immune Signaling Pathways
Eileen Murphy,
Alimentary Health, Ireland
The Pipeline from Concept to Market - Harnessing the Microbiome for Health
The Pipeline from Concept to Market - Harnessing the Microbiome for Health
7:00 PM
On Own for Dinner
8:30—11:45 AM
Antibiotic Resistance, Microbe Killing, and Survival
Main Auditorium
*
Robert A. Britton,
Baylor College of Medicine, USA
Kevin Foster,
University of Oxford, UK
Cooperation and Competition in Bacteria: From Model Systems to the Microbiome
Cooperation and Competition in Bacteria: From Model Systems to the Microbiome
Daniel C. Propheter,
University of Texas Southwestern Medical Center, USA
Short Talk: Adiponectin is a Novel Intestinal Antibacterial Defense Protein
Short Talk: Adiponectin is a Novel Intestinal Antibacterial Defense Protein
Suzanne Devkota,
Cedars-Sinai Medical Center, USA
Creeping Fat: Microbial Translocation Drives Cellular Restructuring of Adipose Tissue in Humans
Creeping Fat: Microbial Translocation Drives Cellular Restructuring of Adipose Tissue in Humans
Coffee Break
Eric G. Pamer,
University of Chicago, USA
Exploiting the Microbiota to Reduce Antibiotic-Resistant Infections
Exploiting the Microbiota to Reduce Antibiotic-Resistant Infections
Sujatha Srinivasan,
Fred Hutchinson Cancer Research Center, USA
Short Talk: Periodic Presumptive Treatment (PPT) with Metronidazole Reduces Abundance of Vaginal Bacteria Associated with HIV Risk
Short Talk: Periodic Presumptive Treatment (PPT) with Metronidazole Reduces Abundance of Vaginal Bacteria Associated with HIV Risk
Ami S. Bhatt,
Stanford University, USA
Mechanisms of Microbial Diversification and Resistance
Mechanisms of Microbial Diversification and Resistance
Takuji Yamada,
Tokyo Institute of Technology, Japan
Short Talk: Metagenomic and Metabolomic Analyses Reveal Distinct Stage-Specific Phenotypes of the Gut Microbiota in Colorectal Cancer
Short Talk: Metagenomic and Metabolomic Analyses Reveal Distinct Stage-Specific Phenotypes of the Gut Microbiota in Colorectal Cancer
11:45 AM—5:00 PM
On Own for Lunch
4:30—5:00 PM
Coffee Available
Foyer
5:00—6:45 PM
Next-Gen Therapeutics and New Frontiers
Main Auditorium
*
Ami S. Bhatt,
Stanford University, USA
Jeff F. Miller,
University of California, Los Angeles, USA
Diversity-Generating Retroelements in Phage, Microbes, and Microbiomes
Diversity-Generating Retroelements in Phage, Microbes, and Microbiomes
Ravi U. Sheth,
Columbia University, USA
Short Talk: Spatial Metagenomic Characterization of Microbial Biogeography in the Gut
Short Talk: Spatial Metagenomic Characterization of Microbial Biogeography in the Gut
Trevor Lawley,
Wellcome Sanger Institute, UK
Integrating Mass Culturing and Metagenomic Analysis for Human Microbiome Translational Science
Integrating Mass Culturing and Metagenomic Analysis for Human Microbiome Translational Science
6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Main Auditorium
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
Foyer
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
Foyer
Departure
*Session Chair †Invited, not yet responded.
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
